Additional file 6: Supplementary Figure 6. Treatment of mice bearing B16-F10 tumors with TMZ in combination with AG-120. A] Sanger sequencing of PCR amplicons correlated with codon 132 of the IDH1 gene in B16-F10 murine melanoma cells. B] Schematic represents the treatment model after 4 × 104 B16-F10 melanoma murine cells were injected subcutaneously into the flanks of C57BL/6 J recipient mice. After 9 days, when tumors reached 80-100 mm3, mice were divided into four groups and treated with i) Vehicle; ii) TMZ (30 mg/kg intraperitoneal once a day); iii) AG-120 (150 mg/kg orally twice a day); and iv) AG-120 + TMZ (150 mg/kg orally twice a day + 30 mg/kg intraperitoneal daily). C] Survival data of C57BL/6 J mice are represented by Kaplan-Meier curves. Significance between each group was determined using the log-rank test.